PD-0299685

PD-0299685
Clinical data
Other namesPD-0299685; PD-299685; PD0299685; PD299685; PD-299,685
Routes of
administration		Oral
Drug classGabapentinoid
ATC code
  • None
Identifiers
  • (3S,5R)-3-(aminomethyl)-5-methyloctanoic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC10H21NO2
Molar mass187.283 g·mol−1
3D model (JSmol)
  • CCC[C@@H](C)C[C@@H](CC(=O)O)CN
  • InChI=1S/C10H21NO2/c1-3-4-8(2)5-9(7-11)6-10(12)13/h8-9H,3-7,11H2,1-2H3,(H,12,13)/t8-,9+/m1/s1
  • Key:KKXFMWXZXDUYBF-BDAKNGLRSA-N

PD-0299685 is a gabapentinoid (α2δ subunit-containing voltage-gated calcium channel blocker) which was under development for the treatment of insomnia and vasomotor symptoms (hot flashes) related to menopause as well as interstitial cystitis. It is taken orally. PD-0299685 was under development by Pfizer. It reached phase 2 clinical trials prior to the discontinuation of its development.

See also

References

  1. 1 2 3 4 5 "PD 0299685". AdisInsight. 5 November 2023. Retrieved 3 October 2025.
  2. ↑ Lewis V (November 2009). "Undertreatment of menopausal symptoms and novel options for comprehensive management". Current Medical Research and Opinion. 25 (11): 2689–2698. doi:10.1185/03007990903240519. PMID 19775194.
  3. ↑ Nickel JC, Crossland A, Davis E, Haab F, Mills IW, Rovner E, et al. (September 2012). "Investigation of a Ca2+ channel α2δ ligand for the treatment of interstitial cystitis: results of a randomized, double-blind, placebo controlled phase II trial". The Journal of Urology. 188 (3): 817–823. doi:10.1016/j.juro.2012.05.010. PMID 22818144.